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Bacterial production and direct functional screening 
of expanded molecular libraries for discovering 
inhibitors of protein aggregation
Dafni C. Delivoria1,2, Sean Chia3, Johnny Habchi3, Michele Perni3, Ilias Matis1, 
Nikoletta Papaevgeniou1,4, Martin Reczko5, Niki Chondrogianni1, Christopher M. Dobson3, 
Michele Vendruscolo3, Georgios Skretas1*
Protein misfolding and aggregation are associated with a many human disorders, including Alzheimer’s and 
Parkinson’s diseases. Toward increasing the effectiveness of early-stage drug discovery for these conditions, 
we report a bacterial platform that enables the biosynthesis of molecular libraries with expanded diversities and 
their direct functional screening for discovering protein aggregation inhibitors. We illustrate this approach by 
performing, what is to our knowledge, the largest functional screen of small-size molecular entities described to 
date. We generated a combinatorial library of ~200 million drug-like, cyclic peptides and rapidly screened it for 
aggregation inhibitors against the amyloid- peptide (A42), linked to Alzheimer’s disease. Through this procedure, 
we identified more than 400 macrocyclic compounds that efficiently reduce A42 aggregation and toxicity in vitro 
and in vivo. Finally, we applied a combination of deep sequencing and mutagenesis analyses to demonstrate 
how this system can rapidly determine structure-activity relationships and define consensus motifs required for 
bioactivity.
INTRODUCTION
The phenomenon of protein misfolding and aggregation is a defining 
feature of a wide range of human diseases with very high socio-
economic impact, including neurodegenerative disorders, type 2 
diabetes, and cancer (1). Since aggregated proteins can cause disease, 
either because they can no longer efficiently perform their physio-
logical function (loss of function) or because they form harmful 
aggregated species with cytotoxic properties (toxic gain of function) 
(1), compounds that prevent, delay, or reverse protein aggregation 
constitute valuable leads for the development of potential therapeutics. 
Μany such molecules are currently in preclinical and clinical devel-
opment (2). As a proof of concept for the therapeutic value of this 
approach, tafamidis, a small molecule that prevents the misfolding 
and aggregation of the carrier protein transthyretin by binding and 
stabilizing its tetrameric native form, has been approved for the 
treatment of familial amyloid polyneuropathy in Europe and Japan 
(Vyndaqel, Pfizer) (3). More recently, migalastat, a chemical rescuer 
of the misfolding of the lysosomal enzyme -galactosidase (4), has 
been approved for the treatment of the lysosomal storage disorder 
Fabry disease in Europe and the United States (Galafold, Amicus 
Therapeutics). Despite these encouraging results, the vast majority 
of protein-misfolding diseases remain incurable, as no disease-modifying 
drug has reached the clinic in most cases. Among the reasons for the 
failure of current clinical trials, we mention an incomplete under-
standing of the exact molecular mechanism of action of the anti–
amyloid- peptide (A) candidates and the late treatment of the 
patients (5). Thus, it is imperative to develop systematic and robust 
approaches to discover previously unidentified and effective disease- 
modifying agents, which are urgently required for this type of disorders.
Advances in key scientific and technological areas are needed to 
increase the success rate with which effective drugs against these 
complex diseases are discovered. One such area is chemical library 
construction. The availability of molecular libraries with expanded 
diversities is expected to markedly increase the chances for identifying 
compounds with the desired properties (6, 7). Because of current 
limitations in organic synthesis and the isolation of natural products, 
however, the diversity of currently tested small-molecule libraries is 
typically not higher than 105 to 106 (8). Considering that the size of 
the chemical space for small molecules, i.e., the number of all possible 
low–molecular weight structures has been estimated to be ~1060 (9), 
it is clear that drug screening efforts will benefit from increased di-
versity. In addition, even when chemical libraries with larger sizes 
are available, the majority of screening methodologies for the iden-
tification of drug-like compounds are not sufficiently high throughput 
to efficiently handle very large libraries. Functional screening assays 
in multiwell plate format, for example, become impractical for libraries 
with more than 106 to 107 members.
Genetically encoded combinatorial libraries can enable a 
marked expansion in the number and chemical complexity of lower– 
molecular weight compounds, which can be generated and subse-
quently tested for bioactivity (7, 10, 11). By using approaches of this 
type, molecular libraries with diversities ranging from many 
millions to even tens of trillions of test compounds have already 
been generated (6, 7, 10, 12, 13), and molecules with valuable bio-
logical activities have been discovered. These bioactivities include 
modulation of the aggregation process of misfolding-prone and disease- 
associated proteins, such as the A and huntingtin (11, 14–17).
One important shortcoming when investigating DNA-encoded 
libraries for protein misfolding and aggregation diseases, however, 
is that they can only be screened for binding against immobilized 
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protein targets (10). Despite their efficiency in identifying strong 
binders, these affinity-based selections cannot readily provide func-
tional information regarding the aggregation inhibition activity 
of the identified hits (10). As a result, the selected binders need to be 
resynthesized chemically and evaluated again for aggregation- 
inhibitory activity in secondary assays. This procedure adds sub-
stantial time, complexity, and cost to the overall screening process 
and is regarded as a major bottleneck by the pharmaceutical industry 
(12). Furthermore, in many cases, the outcome of the selection pro-
cess results in the identification of a large fraction of hits that are 
either completely inactive (12) or have opposite effects on protein 
misfolding and aggregation than the ones intended originally (15).
In an effort to generate new and efficient systems for discovering 
previously unidentified inhibitors of pathogenic protein aggregation, 
we have recently reported the development of a synthetic biology 
platform that enables the discovery of chemical rescuers of disease- 
associated protein misfolding (18). In this system, combinatorial 
libraries of lower–molecular weight peptide macrocycles are bio-
synthesized in Escherichia coli cells and are simultaneously screened 
for their ability to correct the problematic folding of misfolding- 
prone, disease-associated proteins using a flow cytometric ultrahigh- 
throughput genetic screen.
In the present work, we demonstrate how this bacterial discovery 
platform can be expanded to enable the production and direct func-
tional screening of molecular libraries with greatly increased diver-
sities, thus considerably surpassing the capabilities of other systems 
reported to date. We used this system to generate a combinatorial 
library of ~200 million peptide macrocycles and to perform simul-
taneous functional screening for aggregation inhibition activity 
against the 42-residue form of Α (Α42), which is associated 
with Alzheimer’s disease. Within a matter of only a few days, our 
bacterial platform enabled the production and screening of the 
complete library and identified hundreds of hits. Analysis of the 
selected macrocycles revealed that they form different clusters with 
distinct sequence characteristics. Selected macrocycles derived from 
the most dominant clusters were subjected to in vitro biochemical 
and biophysical testing and were found to be highly potent inhibi-
tors of A42 aggregation at substoichiometric ratios. In vivo 
testing in established models of Alzheimer’s disease in the nematode 
Caenorhabditis elegans demonstrated that the selected macrocycles 
were effective in decreasing the deposition of A42 aggregates 
and in markedly reversing A42-induced pathogenic effects. We 
then used a combination of high-throughput sequencing and 
site-directed mutagenesis analyses to determine structure-activity 
relationships for the selected macrocycles and to define consensus 
motifs required for high bioactivity in these molecules. Overall, 
our discovery platform enables the simultaneous production and 
functional screening of molecular libraries with markedly expanded 
diversities for the identification of compounds with therapeutic poten-
tial for inhibiting the aggregation of disease-associated polypeptides.
RESULTS
Construction and characterization of a low-weight  
molecular library with expanded diversity
The molecular libraries that we have chosen to use for the discovery 
of protein aggregation inhibitors are combinatorial libraries of 
head-to-tail cyclic heptapeptides, with an average molecular mass 
of about 770 Da. These macrocycles fall within the class of small 
molecules (molecular mass, <900 Da) but occupy an area of chemical 
space beyond the classical Lipinski’s rule of five (bRo5 space; molecular 
mass, 500 to 1000 Da), where different rules for drug-likeness com-
pared to classical small-molecule therapeutics apply (19, 20). The 
very large number of possible amino acid combinations comprising 
a peptide sequence (of seven amino acids in our case) enables greatly 
expanded levels of molecular diversity compared to available syn-
thetic and natural small-molecule libraries (8). Furthermore, the cyclic 
nature of these molecules affords higher binding affinities for other 
proteins, enhanced ability to penetrate biological barriers, and enhanced 
resistance to proteolysis compared to their linear analogs (21).
Libraries of head-to-tail cyclic peptides can be conveniently pro-
duced in E. coli cells by the “split intein–mediated circular ligation 
of peptides and proteins” (SICLOPPS) method, where a circularly 
permuted split intein catalyzes the formation of a peptide bond 
between the termini of the target protein or peptide (22). SICLOPPS 
is a well-established technique, which has been previously used to 
identify cyclic peptides with different bioactivities (23). The only 
external requirement for the intein splicing reaction and peptide 
cyclization to take place is the presence of a nucleophilic amino acid 
(Cys, Ser, or Thr) as the first amino acid of the to-be-cyclized pep-
tide (18). Thus, to maximize the diversity of our macrocycle library, 
we constructed a combinatorial heptapeptide library with the general 
formula cyclo-NuX1X2X3X4X5X6, where Nu is any one of the nucleo-
philic amino acids Cys, Ser, or Thr and X is any one of the 20 natural 
amino acids. The maximum theoretical diversity of this library is 
3 × 206 = 192 million different sequences. The libraries of genes 
encoding these cyclic heptapeptide libraries were constructed using 
degenerate polymerase chain reaction (PCR) primers, in which the 
randomized amino acids (X) were encoded using randomized NNS 
codons, where N is A, T, G, or C and S is G or C (see Materials and 
Methods). The generated peptide-encoding gene libraries were cloned 
into the vector pSICLOPPS (18) to form the combined pSICLOPPS- 
NuX1X2X3X4X5X6 vector library (Fig. 1A). These vectors express a 
combinatorial library of tetrapartite fusion proteins comprising the 
following: (i) the C-terminal domain of the Ssp DnaE intein (IC), 
(ii) a NuX1X2X3X4X5X6 heptapeptide sequence, (iii) the N-terminal 
domain of the Ssp DnaE intein (IN), and (iv) a chitin- binding domain 
(CBD) for immunodetection and/or purification, under the control 
of the PBAD promoter and its inducer l(+)-arabinose (Fig. 1A). 
Cloning of the resulting gene libraries into the pSICLOPPS plasmid 
yielded a total of 1.2 × 109 independent transformants, as judged by 
plating experiments after serial dilutions.
To assess the quality of our constructed library, we initially chose 
150 randomly selected clones and performed colony PCR and SDS–
polyacrylamide gel electrophoresis (SDS-PAGE)/Western blot. This 
analysis revealed that approximately 45% of the analyzed clones 
contained a DNA insert of the correct size and produced full-length 
IC-peptide-IN-CBD precursor fusion protein (molecular mass, 
~25 kDa), which could undergo processing (appearance of a band 
with a molecular mass of ~20 kDa) (Fig. 1B). Τhis processing is a 
prerequisite for successful intein splicing and indicates possible for-
mation of a cyclic product. According to these results, the generated 
library contains approximately 5.6 × 108 clones that apparently pro-
duce cyclic heptapeptides, a number that covers the theoretical 
diversity of our combined library by almost threefold.
To characterize the constructed library further, we performed deep 
sequencing analysis of the peptide-encoding region of the pSICLOPPS- 
NuX1X2X3X4X5X6 vector library. Of the ~3.4 million plasmid sequences 
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Fig. 1. Construction and characterization of a combinatorial cyclic heptapeptide library with expanded diversity. (A) Left: Representation of the pSICLOPPS-NuX1X2
X3X4X5X6 vector library encoding the combinatorial heptapeptide library cyclo-NuX1X2X3X4X5X6. Nu: Cys, Ser, or Thr; X: any of the 20 natural amino acids; NNS: randomized 
codons, where N = A, T, C, or G and S = G or C; IC: C-terminal domain of the Ssp DnaE split intein; IN: N-terminal domain of the Ssp DnaE split intein. Right: Peptide cyclization 
using the SICLOPPS construct. Upon interaction between the two intein domains IC and IN, the encoded IC-NuX1X2X3X4X5X6-IN-CBD fusions undergo intein splicing and 
peptide cyclization, leading to the production of the cyclo-NuX1X2X3X4X5X6 library. (B) Western blot analysis of 12 randomly picked individual clones from the combinatorial 
heptapeptide library cyclo-NuX1X2X3X4X5X6, showing the expression and processing of the precursor fusion protein IC-peptide-IN-CBD. The 25-kDa band corresponds to 
the unprocessed precursor and the 20-kDa band to the processed IN-CBD construct, and indicates, wherever present, successful intein splicing and peptide cyclization. 
Clone 10, for which the precursor is not expressed, was to contain a stop codon in its peptide-encoding region. (C) Heatmap representation of the amino acid distribution 
at each position of the constructed cyclo-CysX1X2X3X4X5X6 (left), cyclo-SerX1X2X3X4X5X6 (middle), and cyclo-ThrX1X2X3X4X5X6 (right) sublibraries, as demonstrated by the 
deep sequencing analysis results.
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that we analyzed, ~75% were unique at the DNA level and ~95% of 
those were found to encode unique peptide sequences (table S1). 
All amino acids were found to be encoded at every position of the gen-
erated library, albeit with an overrepresentation of residues corre-
sponding to Gly and Arg (Fig. 1C). Together, these results indicate 
that we have constructed a very high-diversity library encoding the 
vast majority, if not all, of the theoretically possible ~192 million 
cyclo-NuX1X2X3X4X5X6 heptapeptide sequences.
Ultrahigh-throughput functional screening for Α42 
aggregation inhibitors
To perform direct functional screening of our vast library of cyclic 
heptapeptides and readily identify bioactive macrocyclic inhibitors 
of pathogenic protein aggregation, we used an ultrahigh-throughput 
system that we previously developed (18). Because of the high 
aggregation propensity of A, E. coli cells overexpressing A42–green 
fluorescent protein (GFP) produce a misfolded fusion that eventually 
accumulates into insoluble inclusion bodies lacking fluorescence (24). 
Conditions that inhibit A aggregation, however, result in the for-
mation of soluble and fluorescent A42-GFP, and bacterial cells 
expressing this fusion acquire a fluorescent phenotype (18, 24). On 
the basis of this, production of the macrocyclic peptide libraries under 
investigation and their screening for misfolding-rescuing activity in 
this system are carried out simultaneously in E. coli cells in an integrated 
fashion, by selecting and isolating the bacterial clones biosynthesizing 
the molecules that enhance the fluorescence of chimeric fusions of 
misfolding-prone proteins with the GFP (Fig. 2A).
Electrocompetent E. coli Tuner (DE3) cells carrying the expres-
sion vector pETA42-GFP (24), which produces A42-GFP under the 
control of the strong bacteriophage T7 promoter, were cotransformed 
with the pSICLOPPS-NuX1X2X3X4X5X6 vector library. Approximately 
3 × 109 transformants carrying both vectors were harvested, pooled 
together, and grown in Luria-Bertani (LB) liquid medium containing 
0.005% l(+)-arabinose—the inducer of cyclic peptide production—
at 37°C with shaking. When the optical density at 600 nm (OD600) 
of the bacterial culture reached a level of about 0.5, 0.1 mM isopropyl- 
-d-thiogalactoside (IPTG) was added to the medium so as to induce 
overexpression of the A42-GFP reporter. After about 2 hours at 
37°C, ~3 × 109 cells were screened, and the population exhibiting the 
top 1 to 3% fluorescence was isolated using fluorescence- activated 
cell sorting (FACS) (fig. S1A). The isolated cells were regrown and 
screened for a total of seven rounds, at which point the mean fluo-
rescence of the population displayed an almost sixfold increase 
compared to the starting library (Fig. 2B). No further substantial in-
crease in fluorescence was observed after additional rounds of sorting.
After the seventh round of FACS screening, 10 individual clones 
were randomly chosen from the sorted population, and their peptide- 
encoding vectors were isolated and then retransformed into fresh E. coli 
Tuner (DE3) cells carrying pET A42-GFP. Protein production was 
induced from both plasmids, and the levels of A42-GFP fluorescence 
of these cultures were measured. A42-GFP fluorescence of the iso-
lated peptide-expressing clones was found to be markedly increased 
compared to cells expressing the same A42-GFP fusion in the presence 
of two random cyclic peptide sequences previously found to have no 
effect on A42-GFP fluorescence and aggregation (Fig. 2C) (18). 
All isolated clones expressed a full-length intein-peptide fusion 
(~25 kDa), which could undergo processing to yield a lower–molecular 
weight band corresponding to excised IN-CBD (~20 kDa), thus sug-
gesting successful intein processing and possible formation of a 
cyclic peptide product (fig. S1B). Furthermore, the observed pheno-
typic effects were dependent on the ability of the Ssp DnaE intein to 
perform protein splicing, as the double amino acid substitution 
H24L/F26A in the C-terminal half of the Ssp DnaE intein, which is 
known to abolish asparagine cyclization at the IC/extein junction and 
prevent extein splicing and peptide cyclization (25), was found to 
reduce A42-GFP fluorescence back to wild-type levels (Fig. 2C and 
fig. S1B). Last, the observed increases in fluorescence were found to 
be A42 specific, as the isolated pSICLOPPS-NuX1X2X3X4X5X6 vectors 
did not enhance the levels of cellular green fluorescence when the 
sequence of A42 was replaced in the same vector with that of the 
DNA-binding (core) domain of human p53 containing a tyrosine to 
cysteine substitution at position 220 [p53C (Y220C)], a protein whose 
misfolding and aggregation is associated with certain forms of cancer 
(fig. S1C) (26).
Analysis of the expressed A42-GFP fusions by SDS-PAGE and 
Western blotting revealed that the bacterial clones expressing the 
selected cyclic heptapeptides produce markedly increased levels of 
soluble A42-GFP compared to random cyclic peptides, despite the 
fact that accumulation of total A42-GFP protein remained at sim-
ilar levels (Fig. 2D, top, and fig. S1D). Furthermore, when the same 
cell lysates were analyzed by native PAGE and Western blotting, we 
observed that coexpression of the selected cyclic peptides reduced 
the accumulation of higher-order A42-GFP aggregates, which could 
not enter the gel, and increased the amounts of species with higher 
electrophoretic mobility (Fig. 2D, bottom left). These higher electro-
phoretic mobility species correspond to the fraction of the total 
A42-GFP that exhibits fluorescence (Fig. 2D, bottom right). Since 
the solubility and fluorescence of bacterially expressed A42-GFP 
has been found to be inversely proportional to the aggregation pro-
pensity of A42 (18, 24, 27), the results described above suggest that 
A42 aggregation is markedly decreased in the presence of the se-
lected cyclic heptapeptides. Similar results were acquired when 
A42 was produced in an unfused, GFP-free form. When we tested 
the effects of the selected cyclic heptapeptides on A42 aggregation 
with an in vivo assay using whole-cell staining of intracellular for-
mation of A42 aggregates with thioflavin S (ThS) (28), we observed 
that coproduction of the selected peptides resulted in decreased levels 
of ThS fluorescence, further indicating a reduced aggregate forma-
tion (Fig. 2E).
DNA sequencing of the 10 selected clones revealed five distinct 
cyclic heptapeptide sequences: cyclo-CKVWQLL (present six times 
among the sequenced clones), cyclo-CRVWTEL, cyclo-CKVWMPL, 
cyclo-CIVVPSI, and cyclo-CRIVPSL (fig. S1E).
High-throughput analysis of the isolated hits
We previously found that low–molecular weight peptide macrocycles 
are a rich source of chemical rescuers of disease-associated protein 
misfolding and aggregation (18). On the basis of that initial obser-
vation, and in combination with the fact that multiple distinct cyclic 
heptapeptide sequences were identified among the 10 selected clones 
initially tested (fig. S1E), we hypothesized that numerous A42- 
targeting macrocyclic sequences may exist among the selected peptide 
pool. To determine the entire ensemble of potentially bioactive cyclic 
heptapeptides present in our library, we performed deep sequencing 
analysis of the heptapeptide-encoding regions in >0.4 million 
pSICLOPPS-NuX1X2X3X4X5X6 vectors contained in the selected 
bacterial population after the seventh round of sorting (Fig. 2B). This 
analysis revealed 416 distinct cyclic heptapeptide sequences appearing at 
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Fig. 2. Biosynthesis and ultrahigh-throughput screening of a combinatorial cyclic heptapeptide library with expanded diversity for discovering inhibitors of protein 
aggregation. (A) Schematic of the used bacterial platform for discovering inhibitors of protein aggregation and for the high-throughput analysis of the selected hits. pMisP-
GFP: plasmid encoding a misfolded protein-GFP fusion; pSICLOPPS-NuX1X2X3X4X5X6: vector library encoding the combinatorial heptapeptide library cyclo-NuX1X2X3X4X5X6; 
Nu: Cys, Ser, or Thr; X:, any of the 20 natural amino acids; FSC-H: forward scatter; SSC-H: side scatter; P: sorting gate. (B) FACS of E. coli Tuner (DE3) cells overexpressing A42-GFP 
and the combined cyclic heptapeptide library. M: mean GFP fluorescence in arbitrary units. FITC-A: filter for fluorescein isothiocyanate. (C) Relative fluorescence of E. coli Tuner 
(DE3) cells overexpressing A42-GFP and 10 randomly selected cyclic heptapeptide clones isolated after the seventh round of FACS shown in (B) and using either the wild-type 
split Ssp DnaE intein (green bars) or the splicing-deficient variant H24L/F26A (white bars) (25). Two randomly picked cyclic peptide sequences (random 1 and 2) previously 
shown to have no effect on Α42-GFP fluorescence and aggregation (18) were used as a negative control. The fluorescence of the bacterial population producing cyclic peptide 
random 1 was arbitrarily set to 100. Mean values ± SEM are presented (n = 3 independent experiments, each performed in three replicates). (D) Top: Western blot analysis of 
total (left) and soluble (right) lysates of E. coli Tuner (DE3) cells overexpressing A42-GFP and the 10 individual cyclic peptide sequences tested in (C). The predicted molecular 
mass of the A42-GFP fusion is ~32 kDa. Bottom: Western blotting using the anti-A antibody 6E10 (left) and in-gel fluorescence (right) analyses of total lysates following native 
PAGE of E. coli Tuner (DE3) cells coexpressing A42-GFP and the 10 individual cyclic peptide sequences tested in (C). (E) Emission spectra of E. coli Tuner (DE3) cells overexpressing 
A42 along with four of the selected cyclic heptapeptide sequences tested in (C) and stained with ThS. The maximum fluorescence of the bacterial population producing cyclic 
peptide random 1 was arbitrarily set to 100. Mean values ± SEM are presented (n = 1 experiment performed in three replicates).
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least 20 times within the sorted population, thus indicating that their 
presence in the selected pool is not coincidental. Cloning of three 
randomly chosen cyclic heptapeptide sequences appearing in the sorted 
pool only with very low frequencies revealed that they are also efficient in 
increasing the fluorescence of bacterially expressed A42-GFP (fig. S1F).
We next performed sequence analysis of the selected cyclic hep-
tapeptides. We found that Cys was the nucleophilic amino acid that 
was present at position 1 in the vast majority of the selected cyclic 
heptapeptides (99.6% of all selected sequences) (Fig. 3A, left). Further-
more, we observed that the frequency of appearance of only a very 
small number of specific amino acids was enriched at each position 
among the selected sequences: Arg and Lys at position 2; Val at po-
sition 3; Trp and Thr at position 4; Ile, Gln, Cys, Met, Ser, Thr, and 
Pro at position 5; Ala, Leu, Val, Glu, Lys, and Pro at position 6; and 
Ile, Leu, and Pro at position 7 (Fig. 3A, right, and table S2). On the 
contrary, the majority of amino acids, including the ones that were 
present in higher abundance in the initial library, were strongly 
de-enriched (Fig. 3A, right, and table S2), thus indicating a highly 
efficient selection process.
To identify potential relationships among the selected cyclic 
heptapeptides, we carried out sequence similarity analysis and 
hierarchical clustering. As the similarity analysis is performed using 
linear sequences, all possible circular permutations of each selected 
cyclic heptapeptide were taken into consideration (fig. S2A). From 
the 416 cyclic heptapeptides selected, 323 of them formed 1467 
unique pairs with more than 70% sequence identity and formed 
20 distinct clusters with similar sequence characteristics (Fig. 3B 
and fig. S2B). Clusters I and II were the most dominant, comprising 
75.0 and 4.9% of the selected bacterial clones, respectively, as well as 
25.7 and 6% of the unique cyclic heptapeptide sequences selected 
(Fig. 3B and table S3). The majority of peptides from clusters I and 
II appeared to belong to a cyclo-CxVWxxx and a cyclo-CxxVPSx motif, 
respectively, in agreement with our previous observations (fig. S1E).
The selected cyclic heptapeptides inhibit  
A42 aggregation in vitro
Two of the selected heptapeptides, cyclo-CKVWQLL and cyclo- 
CRIVPSL, termed AC7-1 and AC7-14 (A-targeting cyclic 
7-peptide number 1 and 14), respectively (Fig. 4A and table S4), 
were chosen for subsequent analysis and were synthetized chemically 
in milligram quantities (fig. S3A). These cyclic peptides were selected 
because they were both encountered in the postselection pool inves-
tigated initially (fig. S1E) and, more importantly, they were the most 
frequently encountered members among the two most dominant 
clusters (clusters I and II) (table S4).
AC7-1 and AC7-14 were initially evaluated by monitoring their 
effects on the kinetics of A42 aggregation by thioflavin T (ThT) 
staining using a highly reproducible approach previously described 
(29, 30). Monomeric A42 was purified after recombinant produc-
tion in E. coli, and aggregation kinetic experiments were initiated 
using 2 M A42 in the absence and presence of AC7-1 and 
AC7-14. Both AC7-1 and AC7-14 inhibited A42 aggregation 
very effectively at substoichiometric ratios as low as 0.5 molar 
equivalents for AC7-1 and 0.1 molar equivalents for AC7-14 
(Fig. 4, B and C). Specifically, we found that both the tlag (time re-
quired for the ThT fluorescence to reach 10% of the total amplitude) 
and tgrowth (transition time from 10 to 90% of the total ThT fluores-
cence amplitude) of the A42 aggregation reaction were increased 
in the presence of the two selected macrocycles, albeit to a different 
extent (Fig. 4, B and C, right). Furthermore, we found that the A42 
fibrils formed after the completion of the aggregation reaction in the 
absence and presence of both AC7-1 and AC7-14 were similar in 
both size and morphology (fig. S3B). Thus, it is likely that these se-
lected macrocycles are not binding irreversibly to A42 species and 
redirecting the aggregation process toward off-pathway aggregates. 
The observed deceleration of A42 aggregation by the selected macro-
cycles could also be observed in the absence of ThT, when the progress 
of the aggregation was monitored by extracting aliquots at different 
time points and probing fibril formation by dot blotting using the 
fibril-specific OC antibody (fig. S3C).
The selected cyclic heptapeptides inhibit  
A42 aggregation and toxicity in vivo
To evaluate the effects of AC7-1 and AC7-14 in vivo, we tested 
their impact on A42 aggregation and A42-induced pathogenicity 
in an established C. elegans model of Alzheimer’s disease. We used 
GMC101, a transgenic strain expressing human A42 in body wall 
muscle cells under the control of a heat-inducible promoter (31). 
Upon temperature upshift, these nematodes (hereafter referred to 
as A worms) exhibit muscle-localized A42 aggregation and even-
tually the emergence of a paralysis phenotype (31). Since the in vitro 
results suggested that the two compounds affect the early stages of 
A42 aggregation, AC7-1 and AC7-14 were administered to the A 
worms before aggregation was initiated. The fitness of the A 
worms—defined as the frequency and speed of body bends—was 
monitored in the absence and presence of AC7-1 and AC7-14 and 
compared to wild-type nematodes, which do not express A42. Both 
peptides increased the motility and speed of the A worms throughout 
their lifetime (Fig. 5, A and B). Both peptides were able to restore 
the total fitness of the A worms to approximately the levels of the 
wild-type animals (Fig. 5C). Furthermore, A worms treated with 
either one of the selected cyclic peptides produced 50 to 60% fewer 
A42 aggregates, as determined by imaging of the worms using the 
amyloid-specific dye 2-{[5ʹ-(4-hydroxyphenyl)(2,2ʹ-bithiophen)-5-yl]- 
methylene}-propanedinitrile (NIAD-4) (Fig. 5, D and E).
To exclude the possibility of promoter- or strain-specific effects, 
we also treated the transgenic C. elegans strain CL4176 with AC7-1 
and AC7-14, which expresses human A42 in its body wall muscle 
cells under a different promoter (32). Consistent with our previous 
observations, the administration of both cyclic peptides resulted in 
a significant delay in the emergence of its characteristic paralysis 
phenotype (fig. S4). These results demonstrate the protective effect 
of the two cyclic peptides in the context of an animal, as shown by 
decrease of A42 deposits, increased locomotion, delay of paralysis, 
and recovery of total fitness.
Structure-activity relationships of AC7-1 and AC7-14
To identify the functionally important residues within the selected 
peptides, we performed nucleophile substitutions at position 1 and 
Ala-scanning mutagenesis at positions 2 to 7 for both AC7-1 and 
AC7-14. Then, we compared the effects of these amino acid sub-
stitutions on the levels of bacterially expressed A42-GFP fluorescence 
and aggregation with those of the selected sequences (positive control) 
and of random cyclic peptide sequences (negative control). For both 
AC7-1 and AC7-14, the substitution of Cys at position 1 with Ser 
resulted in ~50% reduction in fluorescence, while the substitution 
with Thr resulted in levels of A42-GFP fluorescence and aggregation 
similar to those corresponding to the selected sequence (Fig. 6, A and B). 
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B
A
Cluster V
Total sequences: 0.7%
Unique sequences: 2.9%
Cluster IV
Total sequences: 4.1%
Unique sequences: 15.4%
Cluster III
Total sequences: 1.5%
Unique sequences: 10.6%
Cluster II
Total sequences: 4.9%
Unique sequences: 6.0%
Cluster VI
Total sequences: 0.9%
Unique sequences: 3.4%
Cluster I
Total sequences: 75.0%
Unique sequences: 25.7%
Fig. 3. Sequence analysis of the selected cyclic heptapeptide pool. (A) Left: Frequency of appearance of the 20 natural amino acids at each position of the heptapeptide 
sequences selected after the seventh round of sorting (Fig. 2B). Right: Enrichment of the 20 natural amino acids at each position of the heptapeptide sequences selected 
after the seventh round of sorting (Fig. 2B). Values represent the log2-fold change of the amino acid frequency of appearance of the peptides from the sorted pool com-
pared to the initial library. (B) Visualization of the main clusters formed by the selected cyclic heptapeptides according to their sequence similarities. Nodes represent 
different cyclic peptide sequences, and solid lines connect pairs of peptides that share at least 70% sequence identity. The sequences of the members of the two most 
dominant clusters (clusters I and II) are shown in the corresponding dendrograms.
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The latter observation is somewhat unexpected, considering the 
dominant appearance of Cys1 sequences among the selected cyclic 
heptapeptide pool (Fig. 3A, left), but it may be related to our previous 
results, where Thr played a crucial role in the identified cyclic peptides 
against A42 aggregation (18). Since the isolation of the bioactive 
sequences in our system requires repeated rounds of bacterial 
culturing, protein overexpression and FACS, the scarcity of Thr1- 
containing sequences in the isolated cyclic heptapeptide pool may 
be occurring because of a toxicity effect of these sequences on bacterial 
growth, which can result in de-enrichment of the clones that produce 
them, despite their efficiency in preventing protein aggregation.
Furthermore, for both peptides, Ala-scanning mutagenesis at the 
majority of the positions 2 to 7 resulted in markedly A42-GFP 
fluorescence decrease and concomitant increase in aggregation 
(Fig. 6, A and B). Specifically, for AC7-1, substitutions at positions 
2, 3, 4, and 7 resulted in a ~30 to 70% decrease in A42-GFP fluo-
rescence, while for AC7-14, substitutions at all positions except 
Ser6 resulted in a ~45 to 80% decrease (Fig. 6, A and B). These 
observations indicate that a number of residues in both selected cyclic 
heptapeptides are important for optimal aggregation inhibition activity. 
When we performed sequence analysis of all the selected sequences 
belonging to either cluster I or cluster II, we found that the peptides 
appearing most frequently in each cluster have strong preferences 
for specific amino acids at each position. More specifically, for cluster I, 
Arg and Lys at position 2 appeared in >90% of the selected peptides, 
while Val at position 3, Trp at position 4, Gln, Cys, Ser, Met, and Thr 
at position 5, and Ile, Val, and Leu at position 7 appeared in >99% 
of the selected clones (Fig. 6C and table S4). Similarly, for cluster II, 
B
C
A
AβC7-1 AβC7-14
Fig. 4. AC7-1 and AC7-14 inhibit A42 aggregation in vitro. (A) Chemical structures of the selected cyclic heptapeptides AC7-1 and AC7-14. (B) Kinetic profiles of 
the aggregation of 2 M A42 in the absence and presence of AC7-1 at different molar ratios (left) and the normalized t1/2, tlag, and tgrowth values of the corresponding 
aggregation reactions (right). (C) As in (B) for AC7-14. In (B) and (C), mean values ± SEM are presented (n = 1 experiment performed in three replicates).
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Fig. 5. AC7-1 and AC7-14 inhibit A42 aggregation in vivo. (A) Normalized motility (left) and normalized speed of movement (right) of A42 and wild-type worms 
in the absence and presence of 40 Μ AC7-1 and 5 Μ AC7-14 during days 5 to 10 of adulthood. (B) Motility (left) and speed (right) of individual A and wild-type worms 
in the absence and presence of AC7-1 and AC7-14 at day 7 of adulthood. (C) Total fitness (51) of the worms as in (B). (D) Relative fluorescence of A42 and wild-type 
worms at day 7 of adulthood showing a 50 to 60% decrease in A42 aggregate formation in the presence of AC7-1 and AC7-14. (E) Representative images from (D). In 
(A) to (C), ~200 worms were analyzed on average, while in (D), 25 worms were analyzed in total. In all panels, mean values ± SEM are presented (n = number of worms 
tested in one experiment). Statistical significance is denoted by *P ≤ 0.05 and ****P ≤ 0.0001, for differences to the “No peptide A worms” sample.
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Fig. 6. Structure-activity analysis of the selected heptapeptides ΑC7-1 and AC7-14. (A) Relative fluorescence of E. coli Tuner (DE3) cells overexpressing A42-GFP 
and AC7-1 (left) or AC7-14 (right) or the indicated variants thereof as measured by flow cytometry. The fluorescence of the bacterial population coproducing the random 
cyclic peptide was arbitrarily set to 100. Experiments were carried out in triplicate (n = 1 experiment), and the reported values correspond to the mean value ± SEM. 
(B) Western blotting using the anti-A antibody 6E10 (top) and in-gel fluorescence (bottom) analyses following native PAGE of total lysates of E. coli Tuner (DE3) cells 
coexpressing A42-GFP and AC7-1 (left) or AC7-14 (right) along with the indicated variants thereof. (C) Heatmap representation of the amino acid distribution at each 
position of the peptide sequences corresponding to cluster I (Fig. 3B), as demonstrated by the deep sequencing analysis results. The total (left) or the unique (right) hepta-
peptide sequences were included in the analysis. (D) As in (C) for cluster II.
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the frequency of appearance of Arg, Ile, Val, and Gln at position 2 
was ~93%, whereas for Ile and Val at position 3, Val at position 4, 
Pro at position 5, Ser and Ala at position 6, and Ile, Leu, and Val at 
position 7, the frequency of appearance was >97% (Fig. 6D and 
table S4). Together, our results indicate that the most bioactive motifs 
against Α misfolding and aggregation in the investigated macrocycle 
library are cyclo-(C,T) (R,K)VW (,A,M)X (,P) and cyclo-(C,T) 
(I,V)VP (S,A) for clusters I and II, respectively, where X is any 
one of the 20 natural amino acids;  is any one of the polar amino 
acids Q, C, S, and T;  is R, I, V, or Q; and  is any one of the aliphatic 
amino acids L, V, and I.
DISCUSSION
We have reported how a previously developed bacterial platform 
can be expanded to enable the simultaneous production and func-
tional screening of molecular libraries with greatly increased diversities 
for the discovery of inhibitors of disease-associated protein aggre-
gation. We have generated a complete combinatorial library of 
nearly 200 million head-to-tail cyclic heptapeptides in the cytoplasm 
of E. coli cells and have rapidly screened them to discover inhibitors 
of the pathogenic misfolding and aggregation of Α42. We thus found 
head-to-tail cyclic heptapeptides that efficiently reduce A42 aggre-
gation and toxicity both in vitro and in vivo. Our highly effective 
screening methodology, coupled with high-throughput sequenc-
ing analysis of the isolated hits, enabled the identification of >400 
cyclic heptapeptide putative inhibitors of A42 aggregation. In 
addition, these results provide further support to our previous 
observations that low–molecular weight peptide macrocycles are 
a very rich source of chemical rescuers of protein misfolding (18) 
and that they may constitute a promising class of potential thera-
peutics (33).
Our unbiased selection process yielded distinct groups of bioactive 
macrocyclic peptides with different sequence characteristics. For the 
two most dominant clusters, we used a combination of site-directed 
mutagenesis and deep sequencing analyses to rapidly define the 
sequence motifs providing optimal bioactivity. These were found to 
be cyclo-(C,T) (R,K)VW (,A,M)X (,P) for cluster I and cyclo- 
(C,T) (I,V)VP (S,A) for cluster II, where X is any one of the 20 
natural amino acids;  is any one of the polar amino acids Q, C, S, 
or T;  is R, I, V, or Q; and  is any one of the aliphatic amino acids 
L, V, or I. Our in vitro validation indicated that these macrocyclic 
peptides likely exert protective effects by interfering with micro-
scopic reaction steps underlying the aggregation of A, which affect 
the generation of oligomers over time. In the context of an in vivo 
system, as observed in C. elegans, where aggregation proceeds on a 
far longer time scale, this delay in aggregation is much more pro-
nounced and can be considered as effective as an overall arrest of 
the entire process (34).
To our knowledge, the present work describes the largest screen 
of small molecule–like molecular entities with the ability to perform 
direct functional screening beyond simple detection of binding to the 
target protein described to date. Compared to other reported functional 
compound screens for misfolding rescuing or other bioactivities 
in vitro or in vivo (8, 18, 25), we have demonstrated that the system 
that we described has the ability to generate and evaluate molecular 
libraries with 20 to 1000 higher diversity than what can be currently 
achieved. Furthermore, as the diversity of the generated peptide 
macrocycle libraries are limited only by the theoretical diversity of 
the library design and the transformation efficiency of E. coli cells, 
our system can allow the evaluation of libraries with tens or even 
hundreds of billions of members. Notably, E. coli can support the 
biosynthesis of not only head-to-tail cyclic peptides, as investigated 
here, but also side chain–to–tail cyclic peptides (35), bicyclic peptides 
(36), lasso peptides (37), -defensins (38), cyclotides (39), and other 
macrocyclic structures (40) that include both natural and noncanonical 
amino acids (41). Contrary to other approaches that allow the in-
vestigation of even wider areas of molecular space, such as mRNA 
display (10) and DNA-encoded libraries (7, 42), our technology goes 
beyond simple detection of binding to the target protein and, instead, 
selects directly for compounds rescuing aggregation. This is an 
important advantage, since compound resynthesis and testing for 
the desired bioactivity following affinity-based selections of DNA- 
and genetically encoded libraries is time consuming, expensive, and 
results in a high discovery rate of binders that do not exhibit the 
desired biological activity (42).
It is noteworthy that the sequences of the Α42-targeting cyclic 
heptapeptide discovered here diverge completely from those isolated 
from our previous screen that included combinatorial libraries of 
shorter cyclopeptides (18). This result suggests that, apart from the 
specific amino acid residues in the primary sequence of the macro-
cyclic peptide interacting directly with the target protein and are 
necessary for bioactivity (18), there is probably a conformational 
component that is also important for molecular recognition between 
these macrocycles and their targets and that larger cyclopeptide 
scaffolds are not mere extensions of shorter bioactive sequences. 
Furthermore, the selected macrocycles bear no resemblance with the 
sequence of Α42, and thus, their discovery would have been very 
challenging using rational or computationally guided design as, for 
example, in the case of classical  sheet breaker peptides (43) and 
other designed peptide-based inhibitors of A aggregation (44, 45). 
Last, also note that the selected cyclopeptides have drug-like molecular 
characteristics, when compared to those of existing macrocyclic drugs 
and, in some aspects, to those of conventional drugs as well (table S5).
Our biotechnological approach for producing and evaluating 
molecular libraries with expanded diversities is not restricted to 
Α42 but is highly versatile and can be applied broadly for targeting 
a variety of misfolding-prone proteins of both globular and intrinsi-
cally disordered nature, as we have shown previously (18). We are 
currently using this system to screen molecular libraries with expanded 
diversities, such as the ones described here, and have identified can-
didate macrocyclic rescuers of the misfolding and aggregation of 
variants of human Cu/Zn superoxide dismutase and p53, as well 
as of huntingtin, whose misfolding and aggregation are associated 
with amyotrophic lateral sclerosis, cancer, and Huntington’s disease, 
respectively (1).
The biosynthetic production of the lower-weight molecular 
libraries under investigation and their simultaneous screening for 
bioactivity in a simple bacterium like E. coli offer great simplicity and 
speed and reduces the overall cost of the discovery process markedly 
(7, 12). Once the peptide macrocycle library has been constructed, 
one can identify the entire repertoire of aggregation inhibitors for a 
target protein and, at the same time, acquire an initial understanding 
of structure-activity relationships for the acquired hits in less than a 
month. The simplicity, speed, and wide applicability of this approach 
could permit academic and industrial laboratories to simultaneously 
perform parallel screenings against multiple targets and to prioritize 
further compound development according to the number and nature 
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of the hits uncovered by the screen. Overall, our approach represents 
a highly adaptable strategy for investigating molecular libraries with 
expanded diversities, which enables the discovery of New molecular 
entities that effectively target peptides and proteins associated with 
protein misfolding diseases.
MATERIALS AND METHODS
Construction of the combinatorial cyclic  
heptapeptide library
The vector sublibraries pSICLOPPS-CysX1X2X3X4X5X6, pSICLOPPS- 
SerX1X2X3X4X5X6, and pSICLOPPS-ThrX1X2X3X4X5X6 (table S6) 
were generated as described previously (18). Briefly, the degenerate for-
ward primers GS078, GS079, and GS080 were used together with the 
reverse primer GS035 and pSICLOPPS as a template (table S6). Cys, 
Ser, and Thr were encoded in these primers by the codons TGC, AGC, 
and ACC, respectively, while the randomized amino acids (X) were 
encoded using random NNS codons, where N = A, T, G, or C and S = 
G or C. A second PCR reaction was performed in each case to eliminate 
mismatches using the aforementioned amplified DNA fragments as 
templates and the forward primers GS069, GS070, and GS071 for each 
of the peptide sublibraries starting with Cys, Ser, or Thr, respectively, 
together with the reverse primer GS035. The resulting PCR products 
were then digested with Bgl I and Hind III for 5 hours and inserted into 
a similarly digested and dephosphorylated pSICLOPPSKanR vec-
tor (18). The ligation reactions were optimized at a 12:1 insert:vector 
ratio and performed at 16°C for 4 hours. Approximately 10 g of 
the pSICLOPPSKanR vector was used for each sublibrary. The 
ligated DNA was then purified using spin columns, transformed 
into electrocompetent MC1061 cells, plated onto LB agar plates 
containing chloramphenicol (25 g/ml), and incubated at 37°C for 
14 to 16 hours. This process resulted in approximately 1.2 billion 
independent transformants, as judged by plating experiments after 
serial dilutions.
Cyclic heptapeptide library screening
Electrocompetent E. coli Tuner (DE3) cells (Novagen, USA) carrying 
the expression vector pETA42-GFP (24) were cotransformed with 
the combined pSICLOPPS-NuX1X2X3X4X5X6 vector library. Approxi-
mately 109 transformants carrying both vectors were harvested, 
pooled together, and diluted to an OD600 of 0.1 in LB liquid medium 
containing 0.005% l(+)-arabinose to induce cyclic peptide produc-
tion. Cultures were incubated at 37°C with shaking until an OD600 
of 0.4 to 0.5, at which point 0.1 mM IPTG was added to the medium 
to induce overexpression of the A42-GFP reporter. Fluorescence 
of 50,000 cells was recorder after 2 hours of induction at 37°C using 
a BD FACSAria II system (BD Biosciences, USA) with a 488-nm 
solid-state laser for the excitation of GFP and a 530/30 band-pass 
filter for detection. Then, ~3 × 109 cells were gated on a side-scatter 
(SSC-H) versus forward-scatter (FSC-H) plot to eliminate non-
cellular events and were subjected to FACS for the isolation of the 
bacterial population exhibiting the top ~2% fluorescence. The iso-
lated cells were regrown and screened for six additional rounds in 
an identical manner, at which point DNA was isolated from the 
enriched pool using a Qiagen Plasmid Mini Kit.
High-throughput sequencing analysis
High-throughput sequencing analysis was performed at the Genomics 
Core Facility of the Biomedical Sciences Research Center “Alexander 
Fleming” (Athens, Greece) using an Ion Torrent high-throughput 
sequencing platform. Briefly, the combined pSICLOPPS-NuX1X2X3
X4X5X6 vector library and the enriched peptide library after the seventh 
round of sorting were digested with Nco I and BsrG I, and the 
resulting ~250 base pair (bp) products that contained the vari-
able peptide-encoding region were isolated and analyzed. Ion 
proton reads were aligned to a reference sequence using Bowtie2 
(v2.2.8). The alignment information stored in the CIGAR string 
of the resulting Sequence Alignment Map file was parsed and 
mapped to matching and mismatching sequences using the tool 
Biostar59647 of the JVarkit utilities. From the resulting XML file, a 
custom awk script extracted the mismatching insert sequences, 
which were then clustered using the CD-HIT tool (v4.6.1) (46), 
together with their read counts. From the obtained data, only the 
21-bp-long peptide-encoding sequences with NNS codons were 
subjected to further analysis. For the enriched peptide library, all 
sequences including stop codons were also discarded from sub-
sequent analysis.
Peptide sequence similarity analysis and clustering
Sequence similarity analysis was performed using the Immune Epitope 
Database clustering tool (http://tools.iedb.org/cluster2/) and the 
fully interconnected clusters (cliques) method (47). This approach 
allows all peptides in a clique to share a minimal level of identity, 
while at the same time, one peptide can be part of multiple cliques 
(47). As sequence similarity analysis was performed using linear 
sequences, the circular permutants of each cyclic heptapeptide 
appearing at least 20 times within the sorted population were iden-
tified and taken into consideration, tallying up to 2912 linear represent-
ations for the 416 cyclic heptapeptides. From this analysis, 5087 
cliques sharing at least 70% sequence identity were identified, and 
after reintegration of the different circular permutants to their original 
cyclic peptide sequence, 617 unique cliques remained. From the 416 
distinct cyclic heptapeptides, 323 were covered in the cliques forming 
a total of 1467 unique pairs with more than 70% sequence identity. 
The remaining 93 cyclic peptides did not share a minimal level of 
70% identity with any other of the peptides. The results were then 
presented in an undirected network graph using the Gephi graph 
visualization software (48), and cluster identification was performed 
using the Girvan-Newman Algorithm (49).
A42 aggregation kinetic experiments
Kinetic experiments were performed as described previously (30). 
Briefly, appropriate amounts of the synthetic cyclic peptides were 
added to 2 M of monomeric A42 to obtain the desired cyclic 
peptide:Α42 molar ratios, and samples were supplemented with 
20 M ThT, 1% (v/v) acetonitrile, and 0.025% or 0.1% (v/v) Tween 
20 for ΑC7-1 and AC7-14, respectively. Under these conditions, 
both ΑC7-1 and AC7-14 remained stable in a monomeric state 
for the duration of the in vitro experiments, as judged by dynamic 
light scattering analyses. All samples were prepared in low-binding 
Eppendorf tubes on ice using careful pipetting to avoid introduction 
of air bubbles, and each sample was pipetted into three wells of a 96-well 
half-area, low-binding, clear-bottom, polyethylene glycol-coated plate 
(Corning 3881), at 80 l per well. The 96-well plate was then placed at 
37°C under quiescent conditions on a plate reader (Fluostar Omega, 
Fluostar Optima, or Fluostar Galaxy; BMG Labtech), and after excitation 
at 440 nm, ThT fluorescence was measured at 480 nm, through the 
bottom of the plate.
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C. elegans motility
Strains
The following strains were used for this experiment: (i) GMC101, 
herein referred to as A worms; genotype dvIs100 [unc-54p::A-beta- 
1-42::unc-54 3′-UTR + mtl-2p::GFP]; mtl-2p::GFP constitutively 
expresses the GFP in intestinal cells; unc-54p::A-beta-1-42 expresses 
A42 in body wall muscle cells, resulting in A42 aggregation and 
worm paralysis after temperature upshift from 20° to 25°C (31). (ii) 
N2, wild- type C. elegans var Bristol, herein referred to as wild-type 
worms (50).
Propagation procedures
C. elegans worms were propagated using standard conditions and as 
described previously (30, 50). Briefly, the worms were treated with 
hypochlorite bleach, and eggs were hatched overnight in M9 buffer 
[KH2PO4 (3 g/liter), Na2HPO4 (6 g/liter), NaCl (5 g/liter), and 1 mM 
MgSO4] and then distributed on nematode growth medium (NGM) 
[1 mM CaCl2, 1 mM MgSO4, cholesterol (5 mg/ml), 250 mM 
KH2PO4 (pH 6), agar (17 g/liter), NaCl (3 g/liter), and casein (7.5 g/liter)] 
plates seeded with the E. coli OP50 cells and incubated at 20°C. 
Upon reaching the L4 stage, ~700 worms were placed on NGM 
plates containing the desired concentration of the cyclic peptides 
in 1% (v/v) acetonitrile. Synthetic cyclic peptides were provided to 
the nematodes as is, without any additional steps to enhance their 
permeability. At that point, 75 M 5-fluoro-2′deoxyuridine was 
also added to the plates to inhibit growth of offspring. The plates 
were then transferred to 24°C to promote A42 expression and 
aggregation.
Motility assay
On days 5 to 10 of adulthood, worms were collected using M9 buffer 
and distributed on unseeded 9-cm NGM plates. The worms’ move-
ments were recorded at 30 frames/s for 1 min using a homemade 
microscopic setup, and the body bends were quantified using a custom- 
tracking algorithm as described previously (30, 51). In total, ~2300 
worms were analyzed per peptide with an average of ~200 worms 
per experiment. Total fitness refers to the sum of the mobility and 
speed of the worms.
Aggregate quantification
Staining and microscopy were performed as described previously (30). 
Briefly, live animals were stained by incubating with 1 M NIAD-4 
[0.1% (v/v) dimethyl sulfoxide in M9 buffer] for 6 hours at room tem-
perature and then transferred on NGM plates to allow destaining for 
about 16 hours. Stained worms were then anesthetized by adding 40 mM 
NaN3 and mounted on 2% agarose pads on glass microscope slides. 
Images were captured using a Zeiss Axio Observer D1 fluores-
cence microscope (Carl Zeiss Microscopy GmbH) with a 20× ob-
jective and a 49004 ET-CY3/TRITC filter (Chroma Technology 
Corp.), and fluorescence intensity was calculated using the ImageJ 
software (National Institutes of Health). Only the head region of 
the worms was examined because of the high background signal 
in the intestine.
Statistical analyses
Statistical analyses were performed using Prism (GraphPad Software 
Inc., La Jolla, CA, USA), and mean values were compared using un-
paired two-tailed t tests. For animal experiments, group sizes were 
chosen on the basis of prior experience and literature precedence so 
that sufficient numbers remained at the endpoints of the experi-
ment. No samples, worms, or data points were excluded from the 
reported analyses.
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